Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (PARS)

A compound of the formula (I)

• in which
• A is a ring member selected from the group of:
• —CH2-D-, resulting in a fused 6-membered ring which contains D and includes the double bond shown in formula (I), wherein when D is a heteroatom, D is located in the 4-position relative to the nitrogen atom which is bonded to said 6-membered ring, and
• -D-CH2—, resulting in a fused 6-membered ring which contains D and includes the double bond shown in formula (I), wherein when D is a heteroatom, D is located in the 3-position relative to the nitrogen atom which is bonded to said 6-membered ring,
• —CH2CH2CH2—;
• in which
• D represents —CH2—, —O— or —S—,
• E represents (C1–C6)-alkylene or (C3–C8)-cycloalkylene which are optionally mono- or polysubstituted, independently of one another, by substituents selected from the group of (C1–C4)-alkoxy, hydroxyl and amino,
• G represents (C1–C6)-alkylene or (C3–C8)-cycloalkylene which are optionally mono- or polysubstituted, independently of one another, by substituents selected from the group of (C1–C4)-alkoxy, hydroxyl and amino,
• T represents a methylene group,
• t represents 0 or 1,
• U represents (C6–C10)-arylene, 5- to 7-membered heterocyclene having up to three heteroatoms from the group N, O and S or represents ethinediyl, where the ring systems may be substituted up to three times, independently of one another, by substituents selected from the group of nitro, cyano, halogen, (C1–C6)-alkyl, (C3–C8)-cycloalkyl, (C1–C6)-alkoxy, trifluoromethyl, di- and trifluoromethoxy, hydroxyl, amino, mono- and di-(C1–C6)-alkylamino, (C1–C6)-alkoxy-carbonyl, aminosulphonyl, (C1–C6)-alkylsulphonyl, mono- and di-(C1–C6)-alkylaminosulphonyl and (C1–C6)-alkanoyloxy,
• u represents 0 or 1,
• V represents (C6–C10)-arylene, 5-, to 7-membered heterocyclene having up to three heteroatoms from the group N, O and S or represents ethinediyl, where the ring systems may be substituted up to three times, independently of one another, by substituents selected from the group of nitro, cyano, halogen, (C1–C6)-alkyl, (C3–C8)-cycloalkyl, C1–C6)-alkoxy, trifluoromethyl, di- and trifluoromethoxy, hydroxyl, amino, mono- and di-(C1–C6)-alkylamino, (C1–C6)-alkoxy-carbonyl, aminosulphonyl, (C1–C6)-alkylsulphonyl, mono- and di-(C1–C6)-alkylaminosulphonyl and (C1–C6)-alkanoyloxy,
• v represents 0 or 1,
• W represents —O—, —S—, —CO—O—, —O—CO— or —NR4—,
• in which
• R4 represents hydrogen or (C1–C6)-alkyl,
• w represents 0 or 1,
• X represents O, S or N—R5,
• in which
• R5 represents hydrogen, (C1–C6)-alkyl or benzyl,
• Y1 represents hydrogen,
• Y2 represents hydroxyl,
• or
• Y1 and Y2 together represent O, S or N—R6,
• in which
• R6 represents hydrogen, (C1–C6)-alkyl or benzyl,
• R 1 represents hydrogen, (C1–C6)-alkyl which may be mono- or polysubstituted by halogen, or represents (C3–C8)-cycloalkyl,
• R2 represents hydrogen or (C1–C6)-alkoxycarbonyl,
• and
• R3 represents (C6–C10)-aryl or a 5- to 13-membered heterocycle having up to four heteroatoms from the group N, O and S, where the ring systems may be substituted up to three times, independently of one another, by substituents selected from the group of nitro, cyano, halogen, (C1–C6)-alkyl, (C3–C8)-cycloalkyl, (C1–C6)-alkoxy, trifluoromethyl, di- and trifluoromethoxy, hydroxyl, oxo, amino, mono- and di-(C1–C6)-alkylamino, mono- and di-(C1–C6)-alkylaminomethyl, (C1–C6)-alkoxycarbonyl, aminosulphonyl, (C1–C6)-alkylsulphonyl, mono- and di-(C1–C6)-alkylaminosulphonyl, (C1–C6)-alkanoyl, (C1 –C6)-alkanoyloxy and —CH2—R7,
• in which
• R7 represents a 5- to 7-membered heterocycle having up to three heteroatoms from the group N, O and S,
• or a pharmaceutically acceptable salt thereof.